{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=carboplatin&page=29", "query": { "intervention": "carboplatin", "page": 29 }, "page_size": 10 }, "pagination": { "page": 29, "page_size": 10, "total_count": 1996, "total_pages": 200, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=carboplatin&page=30&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=carboplatin&page=28&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T07:40:12.714Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02407600", "title": "Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer", "Vomiting", "Nausea", "Emesis" ], "interventions": [ { "name": "FOSAPREPITANT (Emend)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ajeet Gajra", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2015-04", "completion_date": "2018-02", "has_results": false, "last_update_posted_date": "2015-04-03", "last_synced_at": "2026-10-30T07:40:12.714Z", "location_count": 1, "location_summary": "Syracuse, New York", "locations": [ { "city": "Syracuse", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02407600" }, { "nct_id": "NCT01167192", "title": "Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Radiation therapy", "type": "RADIATION" }, { "name": "Mastectomy (recommended but not mandatory)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 10, "start_date": "2011-02", "completion_date": "2016-09", "has_results": true, "last_update_posted_date": "2016-12-30", "last_synced_at": "2026-10-30T07:40:12.714Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01167192" }, { "nct_id": "NCT00941863", "title": "Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma" ], "interventions": [ { "name": "Sorafenib 100 mg (50-mg tablet)", "type": "DRUG" }, { "name": "Sorafenib 200 mg (50-mg tablet)", "type": "DRUG" }, { "name": "Sorafenib 400 mg (50-mg tablet)", "type": "DRUG" }, { "name": "Sorafenib 400 mg (200-mg tablet)", "type": "DRUG" }, { "name": "Sorafenib 400 mg (Expansion)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 158, "start_date": "2002-07", "completion_date": "2008-04", "has_results": true, "last_update_posted_date": "2016-03-22", "last_synced_at": "2026-10-30T07:40:12.714Z", "location_count": 3, "location_summary": "Philadelphia, Pennsylvania • Nashville, Tennessee • Madison, Wisconsin", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00941863" }, { "nct_id": "NCT00097214", "title": "Carboplatin Plus Cetuximab for Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cetuximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2004-11", "completion_date": "2007-04", "has_results": false, "last_update_posted_date": "2010-04-09", "last_synced_at": "2026-10-30T07:40:12.714Z", "location_count": 8, "location_summary": "Bentonville, Arkansas • Tucker, Georgia • Evanston, Illinois + 5 more", "locations": [ { "city": "Bentonville", "state": "Arkansas" }, { "city": "Tucker", "state": "Georgia" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00097214" }, { "nct_id": "NCT00003701", "title": "Combination Chemotherapy in Treating Patients With Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bladder Cancer", "Urethral Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "vinblastine sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "0 Years to 120 Years" }, "enrollment_count": 490, "start_date": "1999-04-02", "completion_date": "2007-06-15", "has_results": false, "last_update_posted_date": "2023-06-15", "last_synced_at": "2026-10-30T07:40:12.714Z", "location_count": 13, "location_summary": "Decatur, Georgia • Indianapolis, Indiana • Flemington, New Jersey + 9 more", "locations": [ { "city": "Decatur", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Flemington", "state": "New Jersey" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Millville", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003701" }, { "nct_id": "NCT06119581", "title": "A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Neoplasm Metastasis" ], "interventions": [ { "name": "LY3537982", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1264, "start_date": "2023-12-21", "completion_date": "2031-01", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-30T07:40:12.714Z", "location_count": 87, "location_summary": "Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 72 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06119581" }, { "nct_id": "NCT00251498", "title": "Phase II Study of Cetuximab in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Veeda Oncology", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 82, "start_date": null, "completion_date": "2007-10", "has_results": false, "last_update_posted_date": "2008-08-21", "last_synced_at": "2026-10-30T07:40:12.714Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00251498" }, { "nct_id": "NCT03901378", "title": "Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroendocrine Carcinoma", "Large Cell Neuroendocrine Carcinoma of the Lung", "High Grade Neuroendocrine Carcinoma, Any Site" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ochsner Health System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-10-02", "completion_date": "2021-01-21", "has_results": false, "last_update_posted_date": "2021-01-25", "last_synced_at": "2026-10-30T07:40:12.714Z", "location_count": 2, "location_summary": "Kenner, Louisiana • New Orleans, Louisiana", "locations": [ { "city": "Kenner", "state": "Louisiana" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03901378" }, { "nct_id": "NCT00788125", "title": "Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors", "Childhood Germ Cell Tumor", "Extragonadal Germ Cell Tumor", "Kidney Cancer", "Liver Cancer", "Lymphoma", "Neuroblastoma", "Ovarian Cancer", "Sarcoma", "Testicular Germ Cell Tumor", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "dasatinib", "type": "DRUG" }, { "name": "etoposide phosphate", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "microarray analysis", "type": "GENETIC" }, { "name": "western blotting", "type": "GENETIC" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "GENETIC", "OTHER", "PROCEDURE", "RADIATION" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "25 Years", "sex": "ALL", "summary": "1 Year to 25 Years" }, "enrollment_count": 7, "start_date": "2008-09-03", "completion_date": "2022-07-30", "has_results": true, "last_update_posted_date": "2023-07-14", "last_synced_at": "2026-10-30T07:40:12.714Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00788125" }, { "nct_id": "NCT00614484", "title": "Chemotherapy and Proton Radiation for the Treatment of Locally Advanced Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Proton Radiation Therapy", "type": "RADIATION" }, { "name": "Taxol", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Loma Linda University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "1999-08", "completion_date": "2011-06", "has_results": true, "last_update_posted_date": "2014-05-22", "last_synced_at": "2026-10-30T07:40:12.714Z", "location_count": 1, "location_summary": "Loma Linda, California", "locations": [ { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00614484" } ] }